Medigen Biotechnology (ROCO:3176) Cyclically Adjusted Book per Share: NT$15.97 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3176 Medigen Biotechnology Corp ROCO:3176
58 GF Score
Price NT$35.40
GF Value NT$49.63
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Medigen Biotechnology Cyclically Adjusted Book per Share?

Medigen Biotechnology ROCO:3176 +2.31% 58 Cyclically Adjusted Book per Share is NT$15.97 as of Dec. 2025. GuruFocus rates ROCO:3176 with a GF Score™ of 58/100 and a GF Value™ of NT$49.63 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Medigen Biotechnology's adjusted book value per share for the three months ended in Dec. 2025 was NT$11.123. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$15.97 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Medigen Biotechnology's average Cyclically Adjusted Book Growth Rate was -5.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -5.00% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Medigen Biotechnology was 6.00% per year. The lowest was -5.00% per year. And the median was 4.50% per year.

As of today (2026-07-15), Medigen Biotechnology's current stock price is NT$35.40. Medigen Biotechnology's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was NT$15.97. Medigen Biotechnology's Cyclically Adjusted PB Ratio of today is 2.22.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Medigen Biotechnology was 6.38. The lowest was 1.57. And the median was 2.40.


Medigen Biotechnology  (ROCO:3176) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Medigen Biotechnology's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=35.40/15.97
=2.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Medigen Biotechnology was 6.38. The lowest was 1.57. And the median was 2.40.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Medigen Biotechnology Cyclically Adjusted Book per Share Related Terms


Medigen Biotechnology Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Medigen Biotechnology's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medigen Biotechnology Cyclically Adjusted Book per Share Chart

Medigen Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.24 18.60 18.22 16.93 15.97

Medigen Biotechnology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.93 16.78 16.58 16.35 15.97

ROCO:3176 vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Medigen Biotechnology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigen Biotechnology Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigen Biotechnology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Medigen Biotechnology's Cyclically Adjusted PB Ratio falls into.


ROCO:3176
58GF Score
Medigen Biotechnology Corp ROCO:3176
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigen Biotechnology Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medigen Biotechnology's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=11.123/324.0540*324.0540
=11.123

Current CPI (Dec. 2025) = 324.0540.

Medigen Biotechnology Quarterly Data

Book Value per Share CPI Adj_Book
201603 18.289 238.132 24.888
201606 17.271 241.018 23.221
201609 16.647 241.428 22.344
201612 15.873 241.432 21.305
201703 15.095 243.801 20.064
201706 14.451 244.955 19.117
201709 14.328 246.819 18.812
201712 13.249 246.524 17.416
201803 12.949 249.554 16.815
201806 13.186 251.989 16.957
201809 12.472 252.439 16.010
201812 11.084 251.233 14.297
201903 10.902 254.202 13.898
201906 11.430 256.143 14.460
201909 10.798 256.759 13.628
201912 9.793 256.974 12.349
202003 9.819 258.115 12.327
202006 9.705 257.797 12.199
202009 10.349 260.280 12.885
202012 13.062 260.474 16.250
202103 13.595 264.877 16.632
202106 14.084 271.696 16.798
202109 15.420 274.310 18.216
202112 17.181 278.802 19.970
202203 17.775 287.504 20.035
202206 18.106 296.311 19.801
202209 18.239 296.808 19.913
202212 15.734 296.797 17.179
202303 14.133 301.836 15.173
202306 13.634 305.109 14.481
202309 13.377 307.789 14.084
202312 11.422 306.746 12.066
202403 11.174 312.332 11.593
202406 12.029 314.175 12.407
202409 12.059 315.301 12.394
202412 11.355 315.605 11.659
202503 12.105 319.799 12.266
202506 12.139 322.561 12.195
202509 11.774 324.800 11.747
202512 11.123 324.054 11.123

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of NT$15.97 mean?
Medigen Biotechnology (ROCO:3176) has a Cyclically Adjusted Book per Share of NT$15.97 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Medigen Biotechnology and its competitors.
Is Medigen Biotechnology's Cyclically Adjusted Book per Share too high?
Medigen Biotechnology's current Cyclically Adjusted Book per Share is NT$15.97. Overall, Medigen Biotechnology has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medigen Biotechnology's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Medigen Biotechnology's Cyclically Adjusted Book per Share of NT$15.97 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Medigen Biotechnology and its competitors. Medigen Biotechnology's current Cyclically Adjusted Book per Share is NT$15.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Medigen Biotechnology (ROCO:3176) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$49.63, compared to a current price of NT$35.40 — trading 28.7% below its estimated fair value. The current Cyclically Adjusted Book per Share is NT$15.97. Medigen Biotechnology's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Medigen Biotechnology (ROCO:3176), the current Cyclically Adjusted Book per Share is NT$15.97 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued. The current stock price of NT$35.40 is trading 28.7% below its estimated GF Value™ of NT$49.63. GuruFocus considers Medigen Biotechnology to be Modestly Undervalued.

Key valuation signals for ROCO:3176:

  • Cyclically Adjusted Book per Share: NT$15.97
  • GF Value™: NT$49.63 vs. price of NT$35.40 (28.7% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medigen Biotechnology Business Description

Address Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
58GF Score

Get the complete analysis for ROCO:3176

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$35.40
Price
NT$49.63
GF Value